Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INGN 225

Drug Profile

INGN 225

Alternative Names: Ad.p53 DC vaccine; Adenovirus-p53 transduced dendritic cell vaccine; Advexin-based-dendritic-cell-vaccine; Autologous dendritic cell adenovirus p53 vaccine; Dendritic Cell based p53 Vaccine

Latest Information Update: 06 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Vanderbilt-Ingram Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; NewLink Genetics Corporation; University of Nebraska Medical Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; P53 gene stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer

Most Recent Events

  • 31 Jan 2019 H. Lee Moffitt Cancer Center and Research Institute completes a phase II trial in Small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (SC) (NCT00618891) (NCT00617409)
  • 29 Mar 2018 H. Lee Moffitt Cancer Center and Research Institute initiates a phase II trial for Small Cell Lung Cancer (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT03406715)
  • 23 Jan 2018 H. Lee Moffitt Cancer Center and Research Institute plans a phase II trial for Small Cell Lung Cancer (Second-line or greater therapy, Combination therapy) in USA (SC) (NCT03406715)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top